Moreover, it could contribute to inhibiting the migration, proliferation, and invasion of GC cell lines via the YAP/β-catenin pathway, which indicated CBX2 may represent a new therapeutic target of GC [30]. The gene discussed is CBX2; the disease is gastric cancer.